Michael H. Davidson, MD, @mdavidsonmd@NewAmsPharma shares groundbreaking results from the ROSE2 Trial on Obacetrapib!
Discover a remarkable LDL cholesterol reduction with Obacetrapib + Ezetimibe, paving the way for aggressive LDL-C goals. 🎯👏
[video] https://t.co/DpMtKPB7V5
🔬 Marc S. Sabatine, MD, from @BrighamWomens, pioneers MK0616, a Merck PCSK9 inhibitor. LDL cholesterol drops by 60.9% in hypercholesterolemia patients—a potential healthcare game-changer!
[video]https://t.co/LdKqGirk3L
#CardioResearch#LDLCholesterol#Innovation 🌟
📢 Obacetrapib & Edizumab combo ROSE2 positive trial results in reduction of LDL cholesterol.
Watch Michael Davidson @mdavidsonmd@NewAmsPharma discuss the results https://t.co/DpMtKPB7V5
Icosapent Ethyl from 🥼 Professor Philippe Steg's discussion on the REDUCE-IT trial. Exciting to explore the remarkable benefits for patients with recent ACS. @APHP#PhilippeStegMD#ACC23#WCCardio
Watch and Share the Video Here:
https://t.co/I51tabWiz8
Podcast - Epi Scar-Homogenization With VS Without Epicardial Ablation Andrea Natale, MD @natale_md@tcainstitute#VT#ICM
Link to Audio:
https://t.co/SQ7A6Zl00C